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O
ne of the great tragedies of 
our times is the extent to 
which HIV prevention efforts 
are falling short. In 2004, more new 
HIV infections occurred than in any 
previous year: close to 14,000 a day, 
570 per hour, almost ten per minute. 
The greater part of new infections 
occurs in young people, over half in 
persons between 15 and 24 years of 
age, and over half in women. The 
increasing feminization of the HIV/
AIDS epidemic reﬂ  ects the vulnerable 
position of women in many societies 
[1]. HIV is a virus, but inequity is at the 
roots of most of its spread.  
Condoms are highly effective at 
preventing sexual transmission of HIV, 
but only if they are available and used 
[2]. Even if the former is the case, 
women are often in a difﬁ  cult position 
to negotiate use by their male partners 
[3]; this applies to female as well as 
male condoms.
In the absence of an effective 
preventive HIV vaccine [4], which 
is felt to be the only tool that can 
deﬁ  nitively break the epidemic, there 
is thus great need for alternative 
prevention technologies, especially 
those that can be “female-controlled”, 
i.e., use of which does not require 
consent of the male partner. Other 
vulnerable populations might equally 
proﬁ  t from the availability of such 
interventions. The urgent need to 
develop female-controlled prevention 
methods explains the thrust to 
develop vaginal microbicides [5,6], 
and the more recent interest in using 
an antiretroviral oral pre-exposure 
prophylaxis (PREP), for which proof 
of concept has come from preventing 
mother-to-child transmission via 
breastfeeding [7].
Mills and Singh have written an 
informative and thoughtful essay 
for PLoS Medicine on the recent 
interruptions of several tenofovir PREP 
trials, instigated predominantly by 
activist groups, including Act Up–Paris 
[8]. They properly describe what has 
happened in the countries concerned, 
and, at least initially in their essay, they 
do not seem to be afraid of identifying 
culprits, albeit in an indirect way. For 
example, they say, “while freedom 
of expression is a cherished ideal, 
protest should be carried out in a 
responsible manner”, and “speculation, 
unwarranted criticism, overreaction, or 
sensationalizing facts risks stigmatizing 
tenofovir”. But I feel that in the end, 
the authors could have gone further 
in their criticism of the protestors who 
derailed the tenofovir trials and in their 
support for the trial investigators and 
sponsors.  
The fear or trepidation about making 
a correct diagnosis, or being outspoken 
about the correct diagnosis, is in this 
case, as in most other circumstances, 
counterproductive and may even lead 
to more harm being done. The fact of 
the matter is that the investigators of 
the tenofovir trials did consult intensely 
with community groups concerned, but 
this consultative process obviously did 
not include every activist group in the 
world. 
As Co-Chair of last year’s XVth 
International AIDS Conference in 
Bangkok, Thailand, I became painfully 
aware of a structural ﬂ  aw in the system 
of dealing with the activist community. 
The governing body of the conference, 
the Conference Organizing Committee, 
included three international and one 
local Community Co-Organizers, who 
were supposed to have a mandate to 
speak on behalf of the national and 
international AIDS community. In 
the end, though, it turned out that 
agreements on limiting disruption of 
speeches and destruction of property, 
which took endless hours of discussion 
and which were communicated to 
attendants, governments, speakers, 
and sponsors, could not be honored 
because certain activist groups simply 
ignored them. Likewise, in clinical 
research, investigators may end up 
in situations in which they may have 
had an intense dialogue and come 
to an agreement with what they have 
identiﬁ  ed to be the relevant community 
organizations, and yet a day later are 
put on the stand by yet another activist 
group.  
Life would be simpler if there 
were an umbrella organization with 
undisputed leadership among AIDS 
activists that was mandated to speak 
and act on behalf of this community; 
somewhat like labor unions in their 
heydays. But we are far from that. 
Activist groups have now managed 
to derail several PREP trials, arguably 
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Such form of activism 
is only practiced by 
a tiny minority, but 
it has taken us hostage.
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the most important studies for those 
at high risk of acquiring HIV infection 
around the globe. Similarly, activist 
groups have endangered the funding 
and therefore the continuity of the 
International AIDS Conference (the 
only global forum about HIV/AIDS 
where researchers, health-care 
workers, community, activists, drug 
manufacturers, politicians, and leaders 
from all walks of life meet). And 
lately activist groups have prevented 
clinical trials with the promising and 
highly needed new class of CCR5-
receptor-blocking antiretrovirals 
from proceeding in several European 
countries. 
The methods of these speciﬁ  c 
activist groups are uninformed 
demagogy, intimidation, and “AIDS 
exceptionalism”, the last in the sense 
that they exploit their HIV-positive 
status to get away with behavior that 
would not be accepted from others. 
Within the international AIDS 
community, such form of activism is 
only practiced by a tiny minority, but 
it has taken us hostage. Those who will 
suffer the most from the misguided 
ethical imperialism that derailed the 
PREP trials do not live in Paris, but as 
usual in Nairobi, Johannesburg, Phnom 
Penh, and Calcutta.  
There is no other area of medicine 
where activism has been so strong and 
has accomplished so much as in the 
HIV/AIDS ﬁ  eld. Let’s be just a little 
brave, and stand up to protect that 
legacy.  
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